Bacteraemia due to non-ESBL-producing Escherichia coli O25b:H4 sequence type 131: insights into risk factors, clinical features and outcomes - PubMed (original) (raw)
Bacteraemia due to non-ESBL-producing Escherichia coli O25b:H4 sequence type 131: insights into risk factors, clinical features and outcomes
Isabel Morales-Barroso et al. Int J Antimicrob Agents. 2017 Apr.
Abstract
The epidemiology and outcomes of bloodstream infections (BSIs) caused by Escherichia coli ST131 isolates not producing extended-spectrum β-lactamases (ESBLs) are not well defined despite being more prevalent than ESBL-producers. In this study, risk factors and the impact on outcome of BSIs caused by non-ESBL-producing ST131 E. coli versus non-ST131 E. coli were investigated. A case-control study was performed in two tertiary centres to identify risk factors for ST131. Molecular methods were used to investigate all E. coli isolates from blood cultures for those belonging to O25b:H4-ST131 clonal group. fimH alleles were characterised in ST131 isolates. Multivariate analysis was performed by logistic regression or Cox regression as appropriate. A total of 33 ST131 E. coli cases and 56 controls were studied. ST131 isolates showed higher rates of resistance to ampicillin and ciprofloxacin; fimH alleles were H30 in 14 isolates (42.4%) and H22 in 12 isolates (36.4%). Only recent surgery (OR = 7.03, 95% CI 1.71-28.84; P = 0.007) and unknown source of bacteraemia (OR = 5.37, 95% CI 0.93-30.81; P = 0.05) were associated with ST131. ST131 isolates showed no association with 30-day mortality, therapeutic failure, presentation with severe sepsis/shock or length of stay. Bacteraemia due to non-ESBL-producing O25b:H4-ST131 E. coli showed few differences in terms of risk factors as well as similar outcome to non-ST131 E. coli. These data support the notion that ST131 strains are not less clinically virulent despite showing increased antimicrobial resistance, but also that they are not more virulent than other clonal groups causing BSI.
Keywords: Bloodstream infection; Escherichia coli; Mortality; Outcome; Risk factors; ST131.
Copyright © 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
Similar articles
- Molecular and clinical characterization of plasmid-mediated AmpC β-lactamase-producing Escherichia coli bacteraemia: a comparison with extended-spectrum β-lactamase-producing and non-resistant E. coli bacteraemia.
Matsumura Y, Nagao M, Iguchi M, Yagi T, Komori T, Fujita N, Yamamoto M, Matsushima A, Takakura S, Ichiyama S. Matsumura Y, et al. Clin Microbiol Infect. 2013 Feb;19(2):161-8. doi: 10.1111/j.1469-0691.2012.03762.x. Epub 2012 Feb 14. Clin Microbiol Infect. 2013. PMID: 22332968 - Escherichia coli belonging to the worldwide emerging epidemic clonal group O25b/ST131: risk factors and clinical implications.
López-Cerero L, Navarro MD, Bellido M, Martín-Peña A, Viñas L, Cisneros JM, Gómez-Langley SL, Sánchez-Monteseirín H, Morales I, Pascual A, Rodríguez-Baño J. López-Cerero L, et al. J Antimicrob Chemother. 2014 Mar;69(3):809-14. doi: 10.1093/jac/dkt405. Epub 2013 Oct 11. J Antimicrob Chemother. 2014. PMID: 24123431 - Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli in patients with cancer.
Ha YE, Kang CI, Cha MK, Park SY, Wi YM, Chung DR, Peck KR, Lee NY, Song JH. Ha YE, et al. Int J Antimicrob Agents. 2013 Nov;42(5):403-9. doi: 10.1016/j.ijantimicag.2013.07.018. Epub 2013 Sep 7. Int J Antimicrob Agents. 2013. PMID: 24071027 - Escherichia coli ST131, an intriguing clonal group.
Nicolas-Chanoine MH, Bertrand X, Madec JY. Nicolas-Chanoine MH, et al. Clin Microbiol Rev. 2014 Jul;27(3):543-74. doi: 10.1128/CMR.00125-13. Clin Microbiol Rev. 2014. PMID: 24982321 Free PMC article. Review. - Adverse clinical outcomes associated with infections by Enterobacterales producing ESBL (ESBL-E): a systematic review and meta-analysis.
Ling W, Furuya-Kanamori L, Ezure Y, Harris PNA, Paterson DL. Ling W, et al. JAC Antimicrob Resist. 2021 Jun 2;3(2):dlab068. doi: 10.1093/jacamr/dlab068. eCollection 2021 Jun. JAC Antimicrob Resist. 2021. PMID: 35233528 Free PMC article. Review.
Cited by
- Hospital-diagnosed infections with Escherichia coli clonal group ST131 are mostly acquired in the community.
Muller A, Gbaguidi-Haore H, Cholley P, Hocquet D, Sauget M, Bertrand X. Muller A, et al. Sci Rep. 2021 Mar 11;11(1):5702. doi: 10.1038/s41598-021-85116-6. Sci Rep. 2021. PMID: 33707589 Free PMC article. - Clonal ST131-_H_22 Escherichia coli strains from a healthy pig and a human urinary tract infection carry highly similar resistance and virulence plasmids.
Reid CJ, McKinnon J, Djordjevic SP. Reid CJ, et al. Microb Genom. 2019 Sep;5(9):e000295. doi: 10.1099/mgen.0.000295. Epub 2019 Sep 12. Microb Genom. 2019. PMID: 31526455 Free PMC article. - Clinical Impact of Sequence Type 131 in Adults with Community-Onset Monomicrobial Escherichia Coli Bacteremia.
Wang JL, Lee CC, Lee CH, Lee NY, Hsieh CC, Hung YP, Tang HJ, Ko WC. Wang JL, et al. J Clin Med. 2018 Dec 3;7(12):508. doi: 10.3390/jcm7120508. J Clin Med. 2018. PMID: 30513864 Free PMC article. - Success of Escherichia coli O25b:H4 Sequence Type 131 Clade C Associated with a Decrease in Virulence.
Duprilot M, Baron A, Blanquart F, Dion S, Pouget C, Lettéron P, Flament-Simon SC, Clermont O, Denamur E, Nicolas-Chanoine MH. Duprilot M, et al. Infect Immun. 2020 Nov 16;88(12):e00576-20. doi: 10.1128/IAI.00576-20. Print 2020 Nov 16. Infect Immun. 2020. PMID: 32989036 Free PMC article. - Risk Factors and Molecular Features of Sequence Type (ST) 131 Extended-spectrum β-Lactamase-producing Escherichia coli in Community-onset Bacteremia.
Kim H, Kim YA, Park YS, Choi MH, Lee GI, Lee K. Kim H, et al. Sci Rep. 2017 Nov 7;7(1):14640. doi: 10.1038/s41598-017-14621-4. Sci Rep. 2017. PMID: 29116143 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical